A Wilmington federal jury is set to embark on a trade secrets trial next week involving the CEO of Inhibrx. The case raises allegations of improper access to confidential cancer treatment antibody information. The CEO is accused of utilizing this sensitive information while he served as an expert in a $200 million arbitration proceeding unrelated to his role at Inhibrx. The legal community is closely observing this trial due to its implications for corporate governance and the protection of intellectual property within the biotech sector.
As further developments unfold, legal professionals are watching closely given the impact a verdict could have on handling sensitive scientific data in high-stakes corporate environments. Read more about the details of the upcoming trial here.